Genes and epigenetic processes as prospective pain targets

Megan Crow; Franziska Denk; Stephen B McMahon

doi:10.1186/gm416

Genes and epigenetic processes as prospective pain targets

Megan Crow, Franziska Denk, Stephen B McMahon

Wolfson SPaRC

Research output: Contribution to journal › Literature review › peer-review

56 Citations (Scopus)

Abstract

Chronic pain affects approximately one in five adults, resulting in a greatly reduced quality of life and a higher risk of developing co-morbidities such as depression. Available treatments often provide inadequate pain relief, but it is hoped that through deeper understanding of the molecular mechanisms underlying chronic pain states we can discover new and improved therapies. Although genetic research has flourished over the past decade and has identified many key genes in pain processing, the budding field of epigenetics promises to provide new insights and a more dynamic view of pain regulation. This review gives an overview of basic mechanisms and current therapies to treat pain, and discusses the clinical and preclinical evidence for the contribution of genetic and epigenetic factors, with a focus on how this knowledge can affect drug development.

Original language	English
Article number	12
Number of pages	10
Journal	Genome medicine
Volume	5
Issue number	2
DOIs	https://doi.org/10.1186/gm416
Publication status	Published - 15 Feb 2013

Access to Document

10.1186/gm416

Cite this

@article{cfccc13aadcd4ee9b0f2e6f0fca55f2e,

title = "Genes and epigenetic processes as prospective pain targets",

abstract = "Chronic pain affects approximately one in five adults, resulting in a greatly reduced quality of life and a higher risk of developing co-morbidities such as depression. Available treatments often provide inadequate pain relief, but it is hoped that through deeper understanding of the molecular mechanisms underlying chronic pain states we can discover new and improved therapies. Although genetic research has flourished over the past decade and has identified many key genes in pain processing, the budding field of epigenetics promises to provide new insights and a more dynamic view of pain regulation. This review gives an overview of basic mechanisms and current therapies to treat pain, and discusses the clinical and preclinical evidence for the contribution of genetic and epigenetic factors, with a focus on how this knowledge can affect drug development.",

author = "Megan Crow and Franziska Denk and McMahon, {Stephen B}",

year = "2013",

month = feb,

day = "15",

doi = "10.1186/gm416",

language = "English",

volume = "5",

journal = "Genome medicine",

issn = "1756-994X",

publisher = "BioMed Central",

number = "2",

}

TY - JOUR

T1 - Genes and epigenetic processes as prospective pain targets

AU - Crow, Megan

AU - Denk, Franziska

AU - McMahon, Stephen B

PY - 2013/2/15

Y1 - 2013/2/15

N2 - Chronic pain affects approximately one in five adults, resulting in a greatly reduced quality of life and a higher risk of developing co-morbidities such as depression. Available treatments often provide inadequate pain relief, but it is hoped that through deeper understanding of the molecular mechanisms underlying chronic pain states we can discover new and improved therapies. Although genetic research has flourished over the past decade and has identified many key genes in pain processing, the budding field of epigenetics promises to provide new insights and a more dynamic view of pain regulation. This review gives an overview of basic mechanisms and current therapies to treat pain, and discusses the clinical and preclinical evidence for the contribution of genetic and epigenetic factors, with a focus on how this knowledge can affect drug development.

AB - Chronic pain affects approximately one in five adults, resulting in a greatly reduced quality of life and a higher risk of developing co-morbidities such as depression. Available treatments often provide inadequate pain relief, but it is hoped that through deeper understanding of the molecular mechanisms underlying chronic pain states we can discover new and improved therapies. Although genetic research has flourished over the past decade and has identified many key genes in pain processing, the budding field of epigenetics promises to provide new insights and a more dynamic view of pain regulation. This review gives an overview of basic mechanisms and current therapies to treat pain, and discusses the clinical and preclinical evidence for the contribution of genetic and epigenetic factors, with a focus on how this knowledge can affect drug development.

U2 - 10.1186/gm416

DO - 10.1186/gm416

M3 - Literature review

C2 - 23409739

SN - 1756-994X

VL - 5

JO - Genome medicine

JF - Genome medicine

IS - 2

M1 - 12

ER -

Genes and epigenetic processes as prospective pain targets

Abstract

Access to Document

Fingerprint

Cite this